Company Overview
Company Type: Private Company
Website: inversago.com/en
Number of Employees: -
Year Founded: 2015
Total Amount Raised (CAD mm)†: 153.57
Total Rounds of Funding**:3
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Inversago Pharma Inc. operates as a preclinical-stage biotechnology company that engages in the development of peripherally-restricted CB1 receptor (CB1) inverse agonists for the treatment of Prader-Willi syndrome (PWS), diabetes, and metabolic disorders. The company was incorporated in 2015 and is based in Montreal, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Ravenelle, Francois 
Founder & CEO
Vraniak, Glenn S.
Chief Financial Officer
Crater, Glenn D.
Chief Medical Officer
Harvey, Michael D.
Senior Vice President of Drug Development

Key Board Members
Name
Title
Allen, Patricia L.
Director
Incerti, Carlo 
Director
Kim, Dennis D.
Independent Director
Luneborg, Nanna 
Board Member
Mathers, Edward T.
Board Member
Nickerson, Tara 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
1100 René-Lévesque Blvd West Suite 1110 | Montreal, QC | H3B 4N4 | Canada
Phone: 438-300-2534   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Novo Nordisk A/S (CPSE:NOVO B) (Pending)
Aug-10-2023
Unknown
-
-
Amgen Ventures
Oct-17-2022
Minority
-
Series C
New Enterprise Associates, Inc.
Oct-17-2022
Minority
-
Series C
adMare BioInnovations
Sep-08-2020
Unknown
-
Series B
Fonds de solidarité FTQ
Sep-08-2020
Minority
-
Series B


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-10-2023
-
Merger/Acquisition
Target
Inversago Pharma Inc.
Novo Nordisk A/S (CPSE:NOVO B)
Genesys Capital Partners Inc.,Juvenile Diabetes Research Foundation International Inc., Endowment Arm,Accel-Rx,Anges Québec,Tarnagulla Ventures Pty. Ltd.,Amorchem,Forbion Capital Partners B.V.,Fonds de solidarité FTQ,adMare BioInnovations,New Enterprise Associates, Inc.,Amgen Ventures Seller Funds:JDRF T1D Fund, Anges Québec Capital Fund, AmorChem L.P., Forbion IV, Forbion Growth Opportunities Fund I, Forbion Growth Opportunities Fund II, Forbion Ventures Fund IV
1,075.00
Oct-17-2022
Oct-17-2022
Private Placement
Target
Inversago Pharma Inc.
Genesys Capital Partners Inc.,Amorchem,Forbion Capital Partners B.V.,Fonds de solidarité FTQ,adMare BioInnovations,New Enterprise Associates, Inc.,Amgen Ventures Buyer Funds:Forbion IV, Forbion Growth Opportunities Fund I

69.20
Sep-08-2020
Sep-08-2020
Private Placement
Target
Inversago Pharma Inc.
Genesys Capital Partners Inc.,Anges Québec,Amorchem,Forbion Capital Partners B.V.,Fonds de solidarité FTQ,adMare BioInnovations Buyer Funds:JDRF T1D Fund

35.66
Jul-25-2018
Jul-25-2018
Private Placement
Target
Inversago Pharma Inc.
Genesys Capital Partners Inc.,Juvenile Diabetes Research Foundation International Inc., Endowment Arm,Accel-Rx,Anges Québec,Tarnagulla Ventures Pty. Ltd.,Amorchem Buyer Funds:JDRF T1D Fund, Anges Québec Capital Fund, AmorChem L.P.

7.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-10-2023
M&A Transaction Announcements
Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.
May-22-2023
Company Conference Presentations
Inversago Pharma Inc. Presents at American Thoracic Society (ATS) 2023 International Conference, May-22-2023 09:00 AM
Apr-26-2023
Company Conference Presentations
Inversago Pharma Inc. Presents at 2023 Bloom Burton & Co. Healthcare Investor Conference, Apr-26-2023 11:00 AM
Feb-02-2023
Company Conference Presentations
Inversago Pharma Inc. Presents at SVB Securities Global Biopharma Conference, Feb-02-2023
Nov-29-2022
Product-Related Announcements
Inversago Pharma Inc. Doses First Patient in Phase 2 Trial of INV-202

M&A Advisors
Centerview Partners LLC, Goodwin Procter LLP, Osler, Hoskin & Harcourt LLP


Advisors
M&A Advisors
Centerview Partners LLC, Goodwin Procter LLP, Osler, Hoskin & Harcourt LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Infinata, Inc.
Infinata Research
Dec 08, 2020 05:41 AM
Inversago Pharma Inc.
Inversago Pharma, Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 08, 2020 10:03 AM
Inversago Pharma Inc.
Inversago Pharma, Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Jun 16, 2020 05:56 AM
Inversago Pharma Inc.
Inversago Pharma, Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Mar 19, 2020 06:34 AM
Inversago Pharma Inc.
Inversago Pharma, Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Dec 16, 2019 05:42 AM
Inversago Pharma Inc.
Inversago Pharma, Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 30, 2019 05:53 AM
Inversago Pharma Inc.
Inversago Pharma, Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Jun 17, 2019 09:11 AM
Inversago Pharma Inc.
Inversago Pharma, Inc. - Company Report
Reports
8


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Allen, Patricia L.
Director
(617) 648-9792
-

Incerti, Carlo 
Director
(316) 899-3733x5
-
carlo.incerti@forbion.com
Kim, Dennis D.
Independent Director
438-300-2534
-

Luneborg, Nanna 
Board Member
438-300-2534
-

Mathers, Edward T.
Board Member
438-300-2534
-
emathers@nea.com
Nickerson, Tara 
Independent Director
438-300-2534
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Ravenelle, Francois 
Founder & CEO
514 922-2383
-
fravenelle@inversago.com
Vraniak, Glenn S.
Chief Financial Officer
438-300-2534
-

Crater, Glenn D.
Chief Medical Officer
438-300-2534
-

Harvey, Michael D.
Senior Vice President of Drug Development
438-300-2534
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
